logo
  Home | Contact us | Browse | Quick Search by UniProtKB ID, Keyword, PDBID

Menu:

Latest news:

Sep. 10, 2014:
A total of 174 experimentally verified S-nitrosylation sites on 94 S-nitrosylated proteins from individualized human colorectal cancer tissues using a label-free quantitation strategy.

Read more...


Protein Name: Gag-Pol polyprotein

UniprotKB/SwissProt ID: POL_HV1A2 (P03369)

Gene Name: gag-pol

Organism: Human immunodeficiency virus type 1 group M subtype B (isolateARV2/SF2) (HIV-1).

Function: Gag-Pol polyprotein and Gag polyprotein may regulate their own translation, by the binding genomic RNA in the 5'-UTR. At low concentration, Gag-Pol and Gag would promote translation, whereas at high concentration, the polyproteins encapsidate genomic RNA and then shutt off translation (By similarity). Matrix protein p17 has two main functions: in infected cell, it targets Gag and Gag-pol polyproteins to the plasma membrane via a multipartite membrane-binding signal, that includes its myristoylated N-terminus. The second function is to play a role in nuclear localization of the viral genome at the very start of cell infection. Matrix protein is the part of the pre- integration complex. It binds in the cytoplasm the human BAF protein which prevent autointegration of the viral genome, and might be included in virions at the ration of zero to 3 BAF dimer per virion. The myristoylation signal and the NLS thus exert conflicting influences its subcellular localization. The key regulation of these motifs might be phosphorylation of a portion of MA molecules on the C-terminal tyrosine at the time of virus maturation, by virion-associated cellular tyrosine kinase. Implicated in the release from host cell mediated by Vpu (By similarity). Capsid protein p24 forms the conical core that encapsulates the genomic RNA-nucleocapsid complex in the virion. Most core are conical, with only 7% tubular. The core is constituted by capsid protein hexamer subunits. The core is disassembled soon after virion entry. Interaction with human PPIA/CYPA protects the virus from restriction by human TRIM5-alpha and from an unknown antiviral activity in human cells. This capsid restriction by TRIM5 is one of the factors which restricts HIV-1 to the human species (By similarity). Nucleocapsid protein p7 encapsulates and protects viral dimeric unspliced (genomic) RNA. Binds these RNAs through its zinc fingers. Facilitates rearangement of nucleic acid secondary structure during retrotranscription of genomic RNA. This capability is referred to as nucleic acid chaperone activity (By similarity). The aspartyl protease mediates proteolytic cleavages of Gag and Gag-Pol polyproteins during or shortly after the release of the virion from the plasma membrane. Cleavages take place as an ordered, step-wise cascade to yield mature proteins. This process is called maturation. Displays maximal activity during the budding process just prior to particle release from the cell. Also cleaves Nef and Vif, probably concomitantly with viral structural proteins on maturation of virus particles. Hydrolyzes host EIF4GI and PABP1 in order to shut off the capped cellular mRNA translation. The resulting inhibition of cellular protein synthesis serves to ensure maximal viral gene expression and to evade host immune response (By similarity). Reverse transcriptase/ribonuclease H (RT) is a multifunctional enzyme that converts the viral RNA genome into dsDNA in the cytoplasm, shortly after virus entry into the cell. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ribonuclease H (RNase H) activity that cleaves the RNA strand of RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic mode. Conversion of viral genomic RNA into dsDNA requires many steps. A tRNA(3)-Lys binds to the primer-binding site (PBS) situated at the 5'-end of the viral RNA. RT uses the 3' end of the tRNA primer to perform a short round of RNA-dependent minus-strand DNA synthesis. The reading proceeds through the U5 region and ends after the repeated (R) region which is present at both ends of viral RNA. The portion of the RNA-DNA heteroduplex is digested by the RNase H, resulting in a ssDNA product attached to the tRNA primer. This ssDNA/tRNA hybridizes with the identical R region situated at the 3' end of viral RNA. This template exchange, known as minus-strand DNA strong stop transfer, can be either intra- or intermolecular. RT uses the 3' end of this newly synthesized short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of the whole template. RNase H digests the RNA template except for two polypurine tracts (PPTs) situated at the 5'-end and near the center of the genome. It is not clear if both polymerase and RNase H activities are simultaneous. RNase H probably can proceed both in a polymerase-dependent (RNA cut into small fragments by the same RT performing DNA synthesis) and a polymerase-independent mode (cleavage of remaining RNA fragments by free RTs). Secondly, RT performs DNA-directed plus-strand DNA synthesis using the PPTs that have not been removed by RNase H as primers. PPTs and tRNA primers are then removed by RNase H. The 3' and 5' ssDNA PBS regions hybridize to form a circular dsDNA intermediate. Strand displacement synthesis by RT to the PBS and PPT ends produces a blunt ended, linear dsDNA copy of the viral genome that includes long terminal repeats (LTRs) at both ends (By similarity). Integrase catalyzes viral DNA integration into the host chromosome, by performing a series of DNA cutting and joining reactions. This enzyme activity takes place after virion entry into a cell and reverse transcription of the RNA genome in dsDNA. The first step in the integration process is 3' processing. This step requires a complex comprising the viral genome, matrix protein, Vpr and integrase. This complex is called the pre- integration complex (PIC). The integrase protein removes 2 nucleotides from each 3' end of the viral DNA, leaving recessed CA OH's at the 3' ends. In the second step, the PIC enters cell nucleus. This process is mediated through integrase and Vpr proteins, and allows the virus to infect a non dividing cell. This ability to enter the nucleus is specific of lentiviruses, other retroviruses cannot and rely on cell division to access cell chromosomes. In the third step, termed strand transfer, the integrase protein joins the previously processed 3' ends to the 5' ends of strands of target cellular DNA at the site of integration. The 5'-ends are produced by integrase-catalyzed staggered cuts, 5 bp apart. A Y-shaped, gapped, recombination intermediate results, with the 5'-ends of the viral DNA strands and the 3' ends of target DNA strands remaining unjoined, flanking a gap of 5 bp. The last step is viral DNA integration into host chromosome. This involves host DNA repair synthesis in which the 5 bp gaps between the unjoined strands are filled in and then ligated. Since this process occurs at both cuts flanking the HIV genome, a 5 bp duplication of host DNA is produced at the ends of HIV-1 integration. Alternatively, Integrase may catalyze the excision of viral DNA just after strand transfer, this is termed disintegration (By similarity).

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Matrix protein p17: Virion (Potential). Host nucleus (By similarity). Host cytoplasm (By similarity). Host cell membrane; Lipid-anchor (Potential). Note=Following virus entry, the nuclear localization signal (NLS) of the matrix protein participates with

PDB :
( If your security settings prevent Jmol from running, please register http://140.138.144.145/ as a safe location in your Java settings. )

Graphical Visualization of S-nitrosylation Sites:
Overview of Protein S-nitrosylation Sites with Functional and Structural Information
InterPro ID Domain
IPR000071
IPR000477
IPR000721
IPR001037
IPR001584
IPR001878
IPR001969
IPR001995
IPR002156
IPR003308
IPR008916
IPR008919
IPR009007
IPR010659
IPR010661
IPR010999
IPR012337
IPR013084

3D Structure Databases:
3D structure databases
EntryMethodResolution (A)ChainPositionsView
1AID X-ray 2.20 A A/B491-589Link
1B6J X-ray 1.85 A A/B491-589Link
1B6K X-ray 1.85 A A/B491-589Link
1B6L X-ray 1.75 A A/B491-589Link
1B6M X-ray 1.85 A A/B491-589Link
1B6P X-ray 2.00 A A/B491-589Link
1CPI X-ray 2.05 A A/B491-589Link
1D4K X-ray 1.85 A A/B491-589Link
1D4L X-ray 1.75 A A/B491-589Link
1F7A X-ray 2.00 A A/B491-589Link
1KJ4 X-ray 2.90 A A/B/C/D491-589Link
1KJ7 X-ray 2.00 A A/B491-589Link
1KJF X-ray 2.00 A A/B491-589Link
1KJG X-ray 2.00 A A/B491-589Link
1KJH X-ray 2.00 A A/B491-589Link
1KZK X-ray 1.09 A A/B491-589Link
1MT7 X-ray 1.90 A A/B491-589Link
1MT8 X-ray 2.15 A A/B491-589Link
1MT9 X-ray 2.00 A A/B491-589Link
1MTB X-ray 2.50 A A/B491-589Link
1MTR X-ray 1.75 A A/B491-589Link
1N49 X-ray 2.20 A A/B/C/D491-589Link
1T3R X-ray 1.20 A A/B491-589Link
1TSQ X-ray 2.00 A A/B491-589Link
1TSU X-ray 2.10 A A/B491-589Link
1YTG X-ray 2.30 A A/B491-589Link
1YTH X-ray 2.20 A A/B491-589Link
1Z1H X-ray 1.85 A A/B491-589Link
1Z1R X-ray 1.85 A A/B491-589Link
2AID X-ray 1.90 A A/B491-589Link
2F3K X-ray 1.60 A A/B491-588Link
2FGU X-ray 2.00 A A/B491-589Link
2FGV X-ray 1.50 A A/B491-589Link
2FNS X-ray 1.85 A A/B491-589Link
2FNT X-ray 1.44 A A/B491-589Link
2J9J X-ray 1.04 A A/B491-589Link
2J9K X-ray 1.20 A A/B491-589Link
2JE4 X-ray 1.07 A A/B491-589Link
2NXD X-ray 2.00 A A/B491-589Link
2NXL X-ray 2.00 A A/B491-589Link
2NXM X-ray 2.25 A A/B491-589Link
2Q3K X-ray 2.00 A A/B491-589Link
2QHY X-ray 1.85 A A/B491-589Link
2QHZ X-ray 1.85 A A/B491-589Link
2QI0 X-ray 2.10 A A/B491-589Link
2QI1 X-ray 2.00 A A/B491-589Link
2QI3 X-ray 1.95 A A/B491-589Link
2QI4 X-ray 1.80 A A/B491-589Link
2QI5 X-ray 1.85 A A/B491-589Link
2QI6 X-ray 1.85 A A/B491-589Link
2QI7 X-ray 1.85 A A/B491-589Link
3AID X-ray 2.50 A A/B491-589Link
3BXR X-ray 1.60 A A/B491-589Link
3BXS X-ray 1.60 A A/B491-589Link
3EKP X-ray 2.15 A A/B/C/D491-589Link
3EKQ X-ray 2.20 A A/B491-589Link
3EKT X-ray 1.97 A A/B/C/D491-589Link
3EKV X-ray 1.75 A A/B491-589Link
3EKW X-ray 1.60 A A/B491-589Link
3EKX X-ray 1.97 A A/B491-589Link
3EKY X-ray 1.80 A A/B491-589Link
3EL0 X-ray 2.00 A A/B491-589Link
3EL1 X-ray 1.70 A A/B491-589Link
3EL4 X-ray 2.00 A A/B491-589Link
3EL5 X-ray 1.60 A A/B491-589Link
3EL9 X-ray 1.60 A A/B491-589Link
3EM3 X-ray 2.20 A A/B491-589Link
3EM4 X-ray 2.10 A A/B/U/V491-589Link
3EM6 X-ray 2.10 A A/B491-589Link
3FSM X-ray 1.60 A A491-589Link
3GI0 X-ray 1.80 A A/B491-589Link
3GI4 X-ray 1.85 A A/B491-589Link
3GI5 X-ray 1.80 A A/B491-589Link
3GI6 X-ray 1.84 A A/B491-589Link
3HAU X-ray 1.30 A A/B491-589Link
3HAW X-ray 1.30 A A/B491-589Link
3HBO X-ray 1.71 A A/B491-589Link
3HDK X-ray 1.80 A A/B491-589Link
3HLO X-ray 1.60 A A491-589Link
3HVP X-ray 2.80 A A491-589Link
3HZC X-ray 1.45 A A491-589Link
3I2L X-ray 1.50 A A/B491-589Link
3I7E X-ray 1.70 A A/B491-589Link
3IAW X-ray 1.61 A A491-589Link
3KA2 X-ray 1.40 A A491-589Link
3LZV X-ray 2.15 A A/B491-589Link
3MXD X-ray 1.95 A A/B491-589Link
3MXE X-ray 1.85 A A/B491-589Link
3NWQ X-ray 1.50 A A/B491-589Link
3NWX X-ray 1.90 A A/B491-589Link
3NXN X-ray 1.80 A A491-589Link
3NYG X-ray 1.45 A A/B491-589Link
3O9F X-ray 1.70 A A/B491-589Link
3O9G X-ray 1.65 A A/B491-589Link
3O9H X-ray 1.70 A A/B491-589Link
3O9I X-ray 1.45 A A/B491-589Link
3OXV X-ray 1.75 A A/B/C/D491-589Link
3OXW X-ray 1.95 A A/B/C/D491-589Link
3OXX X-ray 1.65 A A/B/C/D491-589Link
3OY4 X-ray 1.76 A A/B491-589Link
3R4B X-ray 1.90 A A/B491-589Link
4EP2 X-ray 1.90 A A491-589Link
4EP3 X-ray 1.81 A A491-589Link
4EPJ X-ray 1.69 A A491-589Link
4EQ0 X-ray 1.70 A A491-589Link
4EQJ X-ray 1.80 A A491-589Link
4F73 X-ray 1.90 A A/B491-589Link
4F74 X-ray 2.20 A A/B491-589Link
4F75 X-ray 1.70 A A/B491-589Link
4F76 X-ray 1.85 A A/B491-589Link
4HVP X-ray 2.30 A A/B491-589Link
7HVP X-ray 2.40 A A/B491-589Link
8HVP X-ray 2.50 A A/B491-589Link

The S-nitrosylation sites of POL_HV1A2

No. Position S-nitrosylated Peptide Secondary Structure of S-nitrosylated Peptide Solvent Accessibility of nitrosylated Site Substrate Motifs PubMed ID Experiment
1557RQYDQIPVEI C GHKAIGTVLV CEEEEEEEEE E CCEEEEEEEE 2.71%N/A22178444-
2557RQYDQIPVEI C GHKAIGTVLV CEEEEEEEEE E CCEEEEEEEE 2.71%N/A9784385-
3557RQYDQIPVEI C GHKAIGTVLV CEEEEEEEEE E CCEEEEEEEE 2.71%N/A11572774-
4585IGRNLLTQIG C TLNFPISPIE HHHHHHHHHC C EEECCCCCCC 4.12%N/A22178444-
5585IGRNLLTQIG C TLNFPISPIE HHHHHHHHHC C EEECCCCCCC 4.12%N/A9784385-
6585IGRNLLTQIG C TLNFPISPIE HHHHHHHHHC C EEECCCCCCC 4.12%N/A11572774-